{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:43:59Z","timestamp":1761824639132,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.advms.2019.09.002","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T23:48:10Z","timestamp":1576194490000},"page":"12-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative effectiveness of 8 versus 12 weeks of Ombitasvir\/Paritaprevir\/ritonavir and Dasabuvir in treatment-na\u00efve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis"],"prefix":"10.1016","volume":"65","author":[{"given":"Dorota","family":"Zar\u0119bska-Michaluk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Piekarska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Jaroszewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Klapaczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W\u0142odzimierz","family":"Mazur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafa\u0142","family":"Krygier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Belica-Wdowik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Baka-\u0106wierz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Janczewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Pabjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Dobracka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Lorenc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Tudrujek-Zdunek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Tomasiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Sitko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksander","family":"Garlicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Czau\u017c-Andrzejuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta","family":"Citko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Dybowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waldemar","family":"Halota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Paw\u0142owska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Laurans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zbigniew","family":"Dero\u0144","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"Buczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta","family":"Bia\u0142kowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Tronina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Flisiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.advms.2019.09.002_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.advms.2019.09.002_bib2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.5114\/ceh.2016.63871","article-title":"Prevalence of HCV genotypes in Poland - the EpiTer study","volume":"2","author":"Flisiak","year":"2016","journal-title":"Clin Exp Hepatol"},{"issue":"6","key":"10.1016\/j.advms.2019.09.002_bib3","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/17474124.2017.1309284","article-title":"Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C","volume":"11","author":"Flisiak","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.advms.2019.09.002_bib4","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S2468-1253(17)30071-7","article-title":"Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial","volume":"2","author":"Welzel","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.advms.2019.09.002_bib5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/jvh.12861","article-title":"Treatment of HCV infection in Poland at the beginning of the interferon-free era-the EpiTer-2 study","volume":"25","author":"Flisiak","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.advms.2019.09.002_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/jir.2017.0113","article-title":"Is interferon-based treatment of viral hepatitis C genotype 3 infection still of value in the era of direct-acting antivirals?","volume":"38","author":"Zar\u0119bska-Michaluk","year":"2018","journal-title":"J Interferon Cytokine Res"},{"issue":"2","key":"10.1016\/j.advms.2019.09.002_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5114\/ceh.2017.67782","article-title":"Recommendations for the treatment of hepatitis C issued by the polish group of HCV experts \u2013 2017","volume":"3","author":"Halota","year":"2017","journal-title":"Clin Exp Hepatol"},{"issue":"1","key":"10.1016\/j.advms.2019.09.002_bib8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/liv.13950","article-title":"Eight weeks of Paritaprevir\/r\/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: results from a real-world cohort","volume":"39","author":"Puigveh\u00ed","year":"2019","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.advms.2019.09.002_bib9","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/apt.13696","article-title":"Comparative effectiveness of ledipasvir\/sofosbuvir\u00b1ribavirin vs. ombitasvir\/paritaprevir\/ritonavir +dasabuvir \u00b1ribavirin in 6961 genotype 1 patients treated in routine medical practice","volume":"44","author":"Backus","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.advms.2019.09.002_bib10","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1053\/j.gastro.2015.07.001","article-title":"Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in a open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis","volume":"149","author":"Lawitz","year":"2015","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.advms.2019.09.002_bib11","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/apt.13790","article-title":"Real-world effectiveness and safety of ombitasvir\/paritaprevir\/ritonavir \u00b1 dasabuvir \u00b1 ribavirin in hepatitis C: AMBER study","volume":"44","author":"Flisiak","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.advms.2019.09.002_bib12","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jhep.2017.01.028","article-title":"Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real-world cohort","volume":"66","author":"Calleja","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.advms.2019.09.002_bib13","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/jgh.13652","article-title":"Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: data from the Veterans administration","volume":"32","author":"Fox","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.advms.2019.09.002_bib14","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s40261-017-0565-5","article-title":"Safety and efficacy of ombitasvir\/paritaprevir\/ritonavir and dasabuvir with or without ribavirin for treatment of hepatitis C virus genotype 1: a systematic review and meta-analysis","volume":"37","author":"Ahmed","year":"2017","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.advms.2019.09.002_bib15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.gastro.2016.05.049","article-title":"Effectiveness of sofosbuvir, ledipasvir\/sofosbuvir, or paritaprevir\/ritonavir\/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs national health care system","volume":"151","author":"Ioannou","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.advms.2019.09.002_bib16","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/jvh.12708","article-title":"Real-world experience with all-oral interferon-free regimen of ombitasvir\/paritaprevir\/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry","volume":"24","author":"Welzel","year":"2017","journal-title":"J Viral Hepat"},{"issue":"5","key":"10.1016\/j.advms.2019.09.002_bib17","doi-asserted-by":"crossref","first-page":"727","DOI":"10.5604\/01.3001.0010.2717","article-title":"Treatment of chronic HCV infection with the new direct acting antivirals (DAA): first report of a real world experience in southern Brazil","volume":"16","author":"Sette","year":"2017","journal-title":"Ann Hepatol"},{"issue":"3","key":"10.1016\/j.advms.2019.09.002_bib18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1590\/s0004-2803.201700000-33","article-title":"Impact of alcohol consumption among patients in hepatitis C virus treatment","volume":"54","author":"Vieira-Castro","year":"2017","journal-title":"Arq Gastroenterol"},{"key":"10.1016\/j.advms.2019.09.002_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.advms.2019.09.002_bib20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40121-017-0163-0","article-title":"Treatment discontinuation, adherence, and real-world effectiveness among patients treated with ledipasvir\/sofosbuvir in the United States","volume":"6","author":"Puenpatom","year":"2017","journal-title":"Infect Dis Ther"},{"issue":"2","key":"10.1016\/j.advms.2019.09.002_bib21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.advms.2017.04.004","article-title":"Effectiveness and safety of ledipasvir\/sofosbuvir\u00b1ribavirin in the treatment of HCV infection: the real-world HARVEST study","volume":"62","author":"Flisiak","year":"2017","journal-title":"Adv Med Sci"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112619300094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112619300094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:40:03Z","timestamp":1761824403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1896112619300094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1896112619300094"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2019.09.002","relation":{},"ISSN":["1896-1126"],"issn-type":[{"type":"print","value":"1896-1126"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of 8 versus 12 weeks of Ombitasvir\/Paritaprevir\/ritonavir and Dasabuvir in treatment-na\u00efve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2019.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V. on behalf of Medical University of Bialystok.","name":"copyright","label":"Copyright"}]}}